Clostridium Difficile Infections Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies – Deinove, Pfizer, MGB Biopharma

February 14 23:50 2023
Clostridium Difficile Infections Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies - Deinove, Pfizer, MGB Biopharma
Delveinsight Business Research LLP
The Clostridium Difficile Infections market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies and the increased research and development programs related to Clostridium Difficile Infections.

Moreover, the positive outcomes of the pipeline candidates during the developmental stage by key players, such as Rebiotix/Ferring Pharmaceuticals, Seres Therapeutics, Aimmune Therapeutics, Summit Therapeutics, Acurx Pharmaceuticals, among others, are also expected to transform the Clostridium Difficile Infections’ treatment scenario.

DelveInsight’s “Clostridium Difficile Infections Market Insights, Epidemiology, and Market Forecast 2032″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Clostridium Difficile Infections market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Clostridium Difficile Infections market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Clostridium Difficile Infections Market

Clostridium Difficile Infections: An Overview

Clostridium difficile Infection (CDI) is a common nosocomial and community-acquired infection caused by gram-positive, anaerobic, spore-forming Clostridium difficile bacteria. It is responsible for about half a million infections in the US yearly. A highly contagious and recurrent disease, it is usually associated with diarrhea and colitis.

The global incidence of the disease is increasing, making it a major public health challenge. Old age, antibiotic exposure, weak immune system, and other illnesses disrupt the microbiota, generating an environment conducive to Clostridium difficile spore germination and vegetative cell outgrowth leading to bacterial overgrowth. Usually found in unhygienic conditions, the bacteria are transmitted via the fecal-oral route, hand-to-hand contact, and airborne environmental dispersal in hospitals.

Clostridium Difficile Infections Market Key Facts

  • The market size of the Clostridium difficile Infection in the seven major markets was approximately USD 413.5 million in 2021, which is further expected to increase by 2032.

  • The United States accounts for the largest market size for Clostridium difficile Infection compared to EU-5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

  • Among EU5 countries, Germany had the highest market size, with approximately USD 19.5 million in 2021. This is expected to increase further, with Germany estimated to capture the maximum market, followed by France in 2032.

  • According to DelveInsight estimates, the total incident cases of Clostridium difficile Infection in the 7MM were found to be approximately 668,700+ cases in 2021.

  • As per DelveInsight analysis, in EU-5, there were approximately 100,004 hospital-acquired Clostridium difficile Infection (HA-CDI) cases and approximately 37,966 community-acquired Clostridium difficile Infection (CA-CDI) cases in 2021, which are expected to increase by 2032.

Clostridium Difficile Infections Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Clostridium Difficile Infections market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Clostridium Difficile Infections market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Clostridium Difficile Infections Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Epidemiology Segmented by –

  • Incident Cases of Clostridium Difficile Infections in the 7MM (2019–2032)

  • Severity-specific Cases of Clostridium Difficile Infections in the 7MM (2019–2032)

  • Age-specific Cases of Clostridium Difficile Infections in the 7MM (2019–2032)

  • Gender-specific Cases of Clostridium Difficile Infections in the 7MM (2019–2032)

Clostridium Difficile Infections Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Clostridium Difficile Infections market or expected to be launched during the study period. The analysis covers the Clostridium Difficile Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Clostridium Difficile Infections pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Clostridium Difficile Infections Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-market

Clostridium Difficile Infections Therapeutics Analysis

The treatment may involve pausing the consumption of antibiotics in the first place, however, as some infections are severe and need long-term antibiotics. The standard of care treatment includes the use of vancomyin, and fidaxomicin. In most cases, the symptoms include after the appropriate treatment with these antibiotics.

To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Currently, Rebiotix is leading the therapeutics market with its Clostridium Difficile Infections (Clostridium Difficile Associated Disease) drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Market Include:

  • Acurx Pharmaceuticals

  • Adiso Therapeutics

  • Biovertis AG

  • Crestone

  • Deinove

  • Destiny Pharma

  • Ferring Pharmaceuticals

  • Finch Therapeutics

  • Lumen Bioscience

  • MGB Biopharma

  • Mikrobiomik Healthcare Company S.L.

  • Pfizer

  • Rebiotix

  • Seres Therapeutics

  • Summit Therapeutics

  • Vedanta Biosciences

And Many Others

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Drugs Covered in the Report Include:

  • ADS 024: Adiso Therapeutics

  • CP101: Finch Therapeutics

  • DNV3837: Deinove

  • Ibezapolstat: Acurx Pharmaceuticals

  • LMN-201:Lumen Bioscience, Inc.

  • MGB-BP-3: MGB Biopharma

  • NTCD-M3: Destiny Pharma

  • PF-06425090 (C. difficile vaccine): Pfizer

  • RBX 2660: Rebiotix

  • REBYOTA (RBX2660): Ferring Pharmaceuticals

  • Ridinilazole: Summit Therapeutics

  • SER 109: Seres Therapeutics

  • VE303: Vedanta Biosciences

And Many More

 

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Clostridium Difficile Infections Competitive Intelligence Analysis

4. Clostridium Difficile Infections Market Overview at a Glance

5. Clostridium Difficile Infections Disease Background and Overview

6. Clostridium Difficile Infections Patient Journey

7. Clostridium Difficile Infections Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Clostridium Difficile Infections Treatment Algorithm, Current Treatment, and Medical Practices

9. Clostridium Difficile Infections Unmet Needs

10. Key Endpoints of Clostridium Difficile Infections Treatment

11. Clostridium Difficile Infections Marketed Products

12. Clostridium Difficile Infections Emerging Drugs and Latest Therapeutic Advances

13. Clostridium Difficile Infections Seven Major Market Analysis

14. Attribute Analysis

15. Clostridium Difficile Infections Market Outlook (In US, EU5, and Japan)

16. Clostridium Difficile Infections Access and Reimbursement Overview

17. KOL Views on the Clostridium Difficile Infections Market

18. Clostridium Difficile Infections Market Drivers

19. Clostridium Difficile Infections Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-market

 

Other Trending Healthcare Reports By DelveInsight

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Insight

“Clostridium Difficile Infections (Clostridium Difficile Associated Disease)- Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: